OptiNose

OptiNose — Corporate Update (April 2024)

26 slides from OptiNose's corporate update, Apr 25, 2024

  1. Slide 1: Building a Leading ENT / Allergy Specialty Company: Commercial Launch Call

    Building a Leading ENT / Allergy Specialty Company Commercial Launch Call April 25, 2024

  2. Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this

  3. Slide 3: Agenda

    3 Agenda Introduction and Corporate Updates Ramy Mahmoud, MD, MPH XHANCE Financial Outlook and Clinical Data in Chronic Sinusitis Ramy Mahmoud, MD, MPH XHANCE Market Opportunity and Updated Commercial Strategy Paul Spence Wrap Up Ramy Mahmoud, MD, MPH

  4. Slide 4: Optinose Overview

    4 Optinose Overview: Differentiated Product: XHANCE is the First and Only FDA-approved medicine for chronic sinusitis (also called chronic rhinosinusitis without nasal polyps) – New market research highlights strong physician preference and intent to use Significant Near-Term Growth Opportunity: XHA

  5. Slide 5: Optinose – Financial Outlook for XHANCE in Chronic Sinusitis

    5 Optinose – Financial Outlook for XHANCE in Chronic Sinusitis We believe strong growth and profitability are possible in our current ENT and Allergy segment Our Leadership team is focused on meeting or exceeding these objectives Growth With the new CS indication XHANCE has peak net revenue potentia

  6. Slide 6: XHANCE: Designed to be Meaningfully Different

    6 XHANCE: Designed to be Meaningfully Different 13 Orange Book listed patents cover XHANCE (last to expire, 2036) Specially shaped, it seals tightly in the nostril, stents the narrow nasal valve, especially the superior part, and shifts intranasal soft tissues Patented sealing and stenting nosepiece

  7. Slide 7: Chronic Sinusitis is a common chronic inflammatory disease

    7 Chronic Sinusitis is a common chronic inflammatory disease • Chronic sinusitis (also called “chronic rhinosinusitis without polyps”) is frequently diagnosed and may or may not be accompanied by comorbid allergies • Persistent inflammation causes pain, swelling, obstruction in deep nasal passages,

  8. Slide 8: Chronic Sinusitis Is One of The Top Adult Physician Visit Diagnoses

    8 Chronic Sinusitis Is One of The Top 3 Adult Physician Visit Diagnoses1 CS accounts for ≈10 million annual office visits, of which ≈70% result in an antibiotic prescription1 ~45% of patients diagnosed with CS underwent sinus surgery, at a mean duration of 4.7 months after initially meeting diagnost

  9. Slide 9: XHANCE Significantly Improved Symptoms in Chronic Sinusitis: ReOpen2

    9 XHANCE Significantly Improved Symptoms in Chronic Sinusitis: ReOpen2 Coprimary Endpoint: LS mean change from baseline to week 4 in composite symptom score (CSS). CSS was the sum of congestion, f acial pain/pressure, and nasal discharge scores. For each symptom 0 = no symptoms and 3 = severe. Sympt

  10. Slide 10: XHANCE Produced Breakthrough Reduction in Risk of Acute Exacerbations of Chronic Sinusitis

    10 XHANCE Produced Breakthrough Reduction in Risk of Acute Exacerbations of Chronic Sinusitis (AECRS) (Pooled data from ReOpen1 and ReOpen2) 1 0.441* 0.343* 0 0.2 0.4 0.6 0.8 1 Type-1 error–controlled analysis of pooled data from ReOpen1 and ReOpen2. Total number of AECRS events (percentage of patie

  11. Slide 11: Despite Patient Dissatisfaction, HCPs Cycle Standard-Delivery Nasal Steroids

    11 Despite Patient Dissatisfaction, HCPs Have Tended To Cycle Standard-Delivery Nasal Steroids Before Escalating Treatment Or Referring For Surgery CRSsNP, chronic rhinosinusitis without nasal polyps; AR, allergic rhinitis 1. Palmer JN, et.al. DOI: https://doi.org/10.1016/j.jaip.2023.12.016​ 2. Palm

  12. Slide 12: The Breakthrough Innovation is the Device – The Exhalation Delivery System

    12 The Breakthrough Innovation is the Device – The Exhalation Delivery System (EDS) OMC, osteomeatal complex. 1. Djupesland PG. Drug Deliv Transl Res. 2013;3(1):42-62. 2. Data on fi le. OptiNose US, Inc. The EDS creates Different Biomechanics During Delivery, Markedly Changing Drug Deposition Sa gi

  13. Slide 13: The EDS Enables Dramatically Different Deposition vs Standard-Delivery Nasal Spray

    13 The EDS Enables Dramatically Different Deposition vs Standard-Delivery Nasal Spray: with EDS, Topical Drug Can Reach Important Sites of Action • The EDS deposits drug in high/deep sinonasal spaces to treat sinus drainage tracts and sinuses • Standard nasal corticosteroid sprays deposit drug almos

  14. Slide 14: Market Opportunity and Updated Commercial Outlook

    Market Opportunity and Updated Commercial Outlook Paul Spence Chief Commercial Officer

  15. Slide 15: FDA Approval of XHANCE Creates Multiple Growth Opportunities

    15 FDA Approval of XHANCE Creates Multiple Growth Opportunities ~70% of patient lives are in an insurance plan that covers XHANCE ~70% of XHANCE prescriptions written are filled Up to ~10 Mi l l ion total patients with CS or NP are diagnosed annually (based on claims data). $10B TAM ~20 Mi l lion ad

  16. Slide 16: Chronic Sinusitis Launch – Expect to Exceed $300M Peak Year Sales

    16 Chronic Sinusitis Launch – Expect to Exceed $300M Peak Year Sales Commercial Foundation Hub Services CS Clinical DataSales Force Robust domestic supply chain with second source of finished goods approved in March (1.5M units) Insurance Coverage (70%) Sales team (75 territories with ~8,000 targets

  17. Slide 17: XHANCE Patient Support Programs

    17 XHANCE Patient Support Programs are Designed to Ensure Patients Receive Maximum Possible Coverage and the Lowest OOP Costs Patient Affordability Solutions Support Navigating Insurance Patient support services powered by Asembia through a mix of technology and staffed patient care coordinators ded

  18. Slide 18: Employing Multiple Channels to Move Targeted HCPs from Awareness to Action

    18 Employing Multiple Channels to Move Targeted HCPs from Awareness to Action 3rd Party Media 3rd Party E-Mail Display / Search Engine Marketing Congresses / Medical Education Detail Aids Speaker Programs Digital Communication Tele Detail Samples / Demos Naive Interested Activate XHANCE Patient Supp

  19. Slide 19: Market research shows HCP intent to prescribe XHANCE increased up to 4-fold

    19 3% 67% 30% 10% 67% 23% 13% 58% 29% 1= Completely unlikely 2= Somewhat unlikely 3= Neither unlikely nor likely 4= Somewhat likely 5= Completely likely Market research shows that HCP’s intent to prescribe XHANCE increased up to 4-fold for both first-and second-line use after exposure to the Chronic

  20. Slide 20: Ramy Mahmoud, MD, MPH, Chief Executive Officer

    Ramy Mahmoud, MD, MPH Chief Executive Officer

  21. Slide 21: Optinose – Incremental Growth Opportunities

    21 Optinose – Incremental Growth Opportunities There is additional growth potential within and beyond our current ENT/Allergy audience Expand in Specialty: We believe there are ROI positive opportunities to expand sales territories (to ~115) in ENT and Allergy based on success/capital availability P

  22. Slide 22: Differentiated Product Offers Significant Opportunity

    22 Differentiated Product Offers Significant Opportunity Fueled by Large Market, High Unmet Need that Is Recognized by Patients and HCPs, Strong Promotional Responsiveness, Limited Competition Large Market Potential CS represents a ~$10 billion annual addressable market potential Highly Differentiat

  23. Slide 23: Optinose Overview

    23 Optinose Overview: Differentiated Product: XHANCE is the First and Only FDA-approved medicine for chronic sinusitis (also called chronic rhinosinusitis without nasal polyps) – New market research highlights strong physician preference and intent to use Significant Near-Term Growth Opportunity: XH

  24. Slide 24: optinose_

    optinose_ ——

  25. Slide 25: Investor Relations

    25 Investor Relations – NASDAQ: OPTN 1 - Optinose is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding the Company’s perfo rmance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Optinose or its ma

  26. Slide 26: Building a Leading ENT / Allergy Specialty Company Commercial Launch Call

    Building a Leading ENT / Allergy Specialty Company Commercial Launch Call April 25, 2024

OptiNose — Corporate Update (April 2024) on 6ix